Prevalence of antineutrophil cytoplasmic antibodies during treatment with benzylthiouracil

Pathologie Biologie

Volumn 57, Issue 5, 2009, Pages 410-414

  Sghiri, R ^a   Ouertani, M ^b   Hsine, H Ben ^a   Slim, I ^a   Chaieb, L ^a   Ghedira, I ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b Centre Hospitalo Universitaire Ibn El Jazzar De Kairouan   (Tunisia)

Author keywords

Antineutrophil cytoplasmic antibodies (ANCA); Benzylthiouracil; Graves' disease; Vasculitis

Indexed keywords

BENZYLTHIOURACIL; CORTICOSTEROID; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAVES DISEASE; HUMAN; HUMAN CELL; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PULMONARY VASCULITIS; TREATMENT DURATION; VASCULITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTITHYROID AGENTS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CHILD; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; THIOURACIL; VASCULITIS; YOUNG ADULT;

EID: 67649216070     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.11.006     Document Type: Article

References (30)

1. Shiran A., Schechnnerb C., and Dickstein G. Propylthiouracil induced agranulocytosis in four patients previously treated with the drug. JAMA 122 (1999) 319-330
2. Aksoy M., and Erdem S. Aplastic anemia after propylthiouracil. Lancet 7556 (1968) 1379
3. Dolman K.M., Gans R.O., Vervaat T.J., Zevenbergen G., Maingay D., Nikkels R.E., et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 342 (1993) 651-652
4. Thabet F., Sghiri R., Tabarki B., Ghedira I., Yacoub M., and Essoussi A.S. ANCA associated diffuse alveolar hemorrhage due to benzylthiouracil. Eur J Pediatr 165 (2006) 435-436
5. Jarraya F., Abid M., Jlidi R., Mkaouar K., Mnif M., Kharrat M., et al. Myeloperoxydase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with benzylthiouracil therapy: report of the first case. Nephrol Dial Transplant 18 (2003) 2421-2423
6. Hachicha M., Kammoun T., Ben Romdhane W., Ben Abdallah R., Mahfoudh A., Kammoun K., et al. Vasculitis with renal involvement and antineutrophil cytoplasmic antibodies in a child receiving benzylthiouracil. Nephrol Ther 3 (2007) 1476-2151
7. Karroud H., Khiari K., Ben Moussa F., Barbouch S., Boussema E., and Ben Maiz H. Vasculitis with renal and pulmonary involvement in a patient receiving benzylthiouracil for Graves' Disease. Rev Med Interne 23 (2002) 857-861
8. Slot M.C., Links T.P., Stegeman C.A., and Teravert J.W. Occurrence of antineutrophil cytoplamic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long follow-up study. Arthritis Rheum 53 (2005) 108-113
9. ten Holder S.M., Joy M.S., and Falk R.J. Cutaneous and systemic manifestations of drug induced vasculitis. Ann Pharmacother 36 (2002) 130-147
10. Vassilopoulos D., Niles J.L., Villa-Forte A., Arroliga A.C., Sullivan E.J., Merkel P.A., et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum 49 (2003) 151-155
11. Savige J., Dimech W., Fritzler M., Goeken J., Hagen E.C., Jennette J.C., et al. Addendum to the international Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control, guidelines, comments, and recommendations of for testing in other autoimmune diseases. Am J Clin Pathol 120 (2003) 312-318
12. Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology 41 (2002) 481-483
13. Yazisiz V, Ongut G, Terzioglu E, Karyalçin U. 2008. Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int J Clin Pract. DOI. 1111/J. 1742-1241.2007.01485.
14. Schultz D.R., and Tozman E.C. Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology and disease associations. Semin arthritis Rheum 25 (1995) 143-157
15. Bosch X., Guilabert A., and Font J. Antineutrophil cytoplasmic antibodies. Lancet 368 (2006) 404-418
16. Sato H., Hattori M., Fujieda M., Sugihara S., Inomata H., Hoshi M., et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 85 (2000) 4270-4273
17. Gunton J.E., Stiel J., Clifton-Bligh P., Wilmshurst E., and McElduff A. Prevalence of positive antineutrophil cytoplasmic antibody (ANCA) in patients receiving antithyroid medication. Eur J Endocrinol 142 (2000) 587-590
18. Sera N., Ashizawa K., Ando T., Abe Y., Ide A., Usa T., et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic. Thyroid 10 (2000) 595-599
19. Kimura S., and Ikeda-Saito M. Human myeloperoxydase and thyroid peroxydase, two enzymes with separate and distinct physiological functions are evolutionary related members of the same gene family. Proteins 3 (1988) 113-120
20. Mariotti S., Anelli S., Ruf J., Bechi R., Czarnocka B., Lombardi A., et al. Comparison of serum thyroid microsomal and thyroid peroxydase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 65 (1987) 987-993
21. Haapala A.M., Soppi E., Hyoty H., Mustonen J., and Pasternack A. Cross-reactivity between antibodies to thyroid microsomal antigens and myeloperoxidase. Lancet 337 (1991) 803
22. Honda H., Shibata T., Hara H., Ban Y., and Sugisaki T. MPO-ANCA in patients with Graves' disease, strong association with propylthiouracil therapy. Sarcoidosis 13 (1996) 280
23. Becker B.A., Fenvez A.Z., and Breslau N.A. Membranous glomerulonephritis associated with Graves' disease. Am J Kidney Dis 33 (1999) 369-373
24. Lam D.C.C., and Lindsay R.H. Accumulation of 2-14C propylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol 28 (1979) 2289-2296
25. Lee E., Hirouchi M., Hosokawa M., Sayo H., Kohno M., and Kariya K. Inactivation of peroxidase of rate bone marrow by repeated administration of propylthiouracil is accompanied by a change of the heme structure. Biochem Pharmacol 37 (1988) 2152-2153
26. Williams J.M., Kamesh L., and Savage C.O. Translating basic science into patients therapy for ANCA associated small vessel vasculitis. Clin Sci 108 (2005) 101-112
27. Ye H., Gao Y., Guo X.H., and Zhao M.H. Titre and affinity of propylthiouracil induced antimyeloperoxidase antibodies are closely associated with the development of clinical vasculitis. Clin Exp Immunol 142 (2005) 116-119
28. Yu F., Chen M., Gao Y., Wang S.X., Zou W.Z., Zhao M.H., et al. Clinical and pathological features of renal involvement in propylthiouracil associated ANCA positive vasculitis. Am J Kidey Dis 5 (2007) 607-614
29. Yu F., Zhao M.H., Zhang Y.K., Zhang Y., and Wang H.Y. Antiendothelial cell antibodies (AECA) in patients with propylthiouracil induced ANCA positive vasculitis are associated with disease activity. Clin Exp Immunol 139 (2005) 569-574
30. Tieulie N., Huong D.L.T., Andreu M., Wechsler B., Mercadal L., Beaufils H., et al. ANCA associated glomerulonephritis related to benzylthiouracil. Rev Med Interne 23 (2002) 853-856